Eli Lilly and Company (NYSE:LLY) price on Friday, March 17, fall -0.11% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $329.18.
A look at the stock’s price movement, the close in the last trading session was $329.53, moving within a range at $328.10 and $334.946. The beta value (5-Year monthly) was 0.35 while the PE ratio in trailing twelve months stood at 47.64. Turning to its 52-week performance, $384.44 and $276.45 were the 52-week high and 52-week low respectively. Overall, LLY moved -1.74% over the past month.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Eli Lilly and Company’s market cap currently stands at around $315.31 billion, with investors looking forward to this quarter’s earnings report slated for Apr 27, 2023. The company has a Forward Dividend ratio of 4.52, with its dividend yield at 1.37%. As such, investors might be keen on an upside in the stock’s price ahead of the scheduled earnings report. Analysts project the company’s earnings per share (EPS) to be $1.81, which has seen fiscal year 2023 EPS growth forecast to increase to $8.5 and about $11.71 for fiscal year 2024. Per the data, EPS growth is expected to be 7.10% for 2023 and 37.80% for the next financial year.
Analysts have a consensus estimate of $6.85 billion for the company’s revenue for the quarter, with a low and high estimate of $6.54 billion and $7.28 billion respectively. The average forecast suggests down to a -12.30% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue for 2023 to grow to $30.65 billion, representing a 7.40% jump on that reported in the last financial year.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that LLY is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
25 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 7 analyst(s) rate the stock as a Hold, 16 recommend LLY as a Buy and 1 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 1 say it is a Sell. As such, the average rating for the stock is Overweight which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
The technical evaluation for the stock shows the PEG ratio is 2.08, with LLY’s current price about 2.54% and -2.37% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 52.42, while 7-day volatility ratio is 2.53% and 2.30% in the 30-day chart. Further, Eli Lilly and Company (LLY) has a beta value of 0.35, and an average true range (ATR) of 8.18. Analysts have given the company’s stock an average 52-week price target of $378.86, forecast between a low of $270.00 and high of $444.00. Looking at the price targets, the low is 17.98% off current price level while to achieve the yearly target high, price needs to move -34.88%. Nonetheless, investors will most likely welcome a -20.75% jump to $397.50 which is the analysts’ median price.
In the market, a comparison of Eli Lilly and Company (LLY) and its peers suggest the former has performed considerably weaker. Data shows LLY’s intraday price has changed -0.11% in last session and 19.08% over the past year. Comparatively, Johnson & Johnson (JNJ) has moved -1.07% on the day and only -12.69% in the past 12 months. Looking at another peer, we see that Rogers Corporation (ROG) price has dipped -1.81% on the day. However, the stock is -45.12% off its price a year ago. If we look at the PE ratio, we find that Eli Lilly and Company’s ratio stands at 47.64 compared to Johnson & Johnson’s 22.62 and Rogers Corporation’s 24.28. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are down -1.10% and -1.19% respectively in the last trading.
If we refocus on Eli Lilly and Company (NYSE:LLY), historical trading data shows that trading volumes averaged 3.69 million over the past 10 days and 2.93 million over the past 3 months. The company’s latest data on shares outstanding shows there are 952.35 million shares.
The 10.90% of Eli Lilly and Company’s shares are in the hands of company insiders while institutional holders own 84.80% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 4.93 million on Jan 30, 2023, giving us a short ratio of 1.94. The data shows that as of Jan 30, 2023 short interest in Eli Lilly and Company (LLY) stood at 0.52% of shares outstanding, with shares short falling to 5.62 million registered in Dec 29, 2022. Current price change has pushed the stock -10.02% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the LLY stock continues to rise going into the next quarter.